HALO Halozyme Therapeutics, Inc. stock chart & analysis
Conviction 47HealthcareScan · Fri, Nov 6, 2026Halozyme Therapeutics, Inc. (HALO) closed at $103.63 (-15.72%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 29, RS Rating 94, -22.6% from its 52-week high, +54.1% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Financials as of Wed, Sep 30, 2026 · quarterly.
HALO technical analysis
Trend
HALO's moving averages are mixed — no clean uptrend or downtrend. It closed 10.0% below the 50-day ($115.19) and 22.5% above the 200-day ($84.66). ADX(14) at 37 points to a strong, established trend. It meets 7 of 8 trend-template criteria.
Momentum
RSI(14) is 29, in oversold territory. MACD crossed below its signal line one session ago. Its RS Rating of 94 puts its weighted 12-month performance ahead of about 94% of the US market.
Volume and volatility
Volume on the latest session ran 3.7× its 20-day average. It trades about $297.9M a day on average. ATR(14) is $4.94, 4.8% of price — its typical daily range.
Key levels
The chart pattern's support is $106.08 and its resistance $125.42. The 52-week range is $61.23 to $134.00; price is 22.6% below the high and 69.4% above the low. The VWAP anchored at the 52-week high is $120.01, above price.
Performance
HALO returned -20.8% (1 week), -5.6% (1 month), +1.0% (3 months), +61.7% (6 months), +51.8% (1 year), +54.1% (year to date).
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Biological Products, (No Diagnostic Substances) · Listed 2004 · 423 employees
Recent news
- Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029PR Newswire · Fri, Nov 6, 2026
- U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck CancerPR Newswire · Fri, Nov 6, 2026
- HALOZYME THERAPEUTICS, INC.: Earnings resultsSEC EDGAR · Thu, Nov 5, 2026
Congress activity
Disclosed STOCK Act trades in HALO · 2 recent
Insider activity
SEC Form 4 transactions in HALO · open-market 7 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Posard Matthew L. Director · Common Stock · 2026-09-16 | Sell | 3K | $320K | 2026-09-16 | 2026-09-17 |
Posard Matthew L. Director · Common Stock · 2026-09-16 | Sell | 3.1K | $329K | 2026-09-16 | 2026-09-17 |
Posard Matthew L. Director · Common Stock · 2026-09-16 | Sell | 8.9K | $961K | 2026-09-16 | 2026-09-17 |
Posard Matthew L. Director · Common Stock · 2026-09-16 | Sell | 4K | $436K | 2026-09-16 | 2026-09-17 |
Torley Helen PRESIDENT AND CEO · Option to Purchase Common Stock · 2026-09-11 | Exercise | 20K | $368K | 2026-09-11 | 2026-09-11 |
Torley Helen PRESIDENT AND CEO · Common Stock · 2026-09-11 | Exercise | 20K | $368K | 2026-09-11 | 2026-09-11 |
Torley Helen PRESIDENT AND CEO · Common Stock · 2026-09-11 | Sell | 15.49K | $1.7M | 2026-09-11 | 2026-09-11 |
Torley Helen PRESIDENT AND CEO · Common Stock · 2026-09-11 | Sell | 4.51K | $485K | 2026-09-11 | 2026-09-11 |
Torley Helen PRESIDENT AND CEO · Common Stock · 2026-09-10 | Exercise | 20K | $368K | 2026-09-10 | 2026-09-11 |
Torley Helen PRESIDENT AND CEO · Common Stock · 2026-09-10 | Sell | 14.59K | $1.6M | 2026-09-10 | 2026-09-11 |
SEC filings
EDGAR filings in HALO · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.